PPARγ agonist-22 

PPARγ agonist-22 is a PPARγ agonist. PPARγ agonist-22 promotes cellular glucose uptake. PPARγ agonist-22 reduces lipid accumulation in adipocytes. PPARγ agonist-22 can be used in the research of type 2 diabetes^[1].

PPARγ agonist-22 (Compound Sn8) (12.5-200 μg/mL; 24 h) shows no cytotoxicity to 3T3-L1 preadipocytes and C2C12 myoblasts at low concentrations, but induces concentration-dependent cytotoxicity at high concentrations^[1].
PPARγ agonist-22 (25 μg/mL; 8 days) exhibits anti-adipogenic activity in 3T3-L1 preadipocytes, reducing lipid accumulation to 61.03% of the control level after 8 days of differentiation^[1].
PPARγ agonist-22 (100 μg/mL; 24 h) significantly increases glucose uptake in C2C12 myoblasts^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

465.57

C₂₇H₂₃N₅OS

931956-54-6

O=C(C1=CC=C(C=C1)CN2C(SCC3=CC=CC=C3)=NC4=C2C=NC=C4)NCC5=NC=CC=C5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Nath V, et al. Identification of antidiabetic leads using in-silico screening, molecular dynamics simulation, and biological evaluation using cell viability, anti-adipogenesis, glucose uptake, and peroxisome proliferator activated receptor-γ in-vitro assay. J Comput Aided Mol Des. 2026;40(1):48. Published 2026 Jan 13.  [Content Brief]